Invitrogen™ P-cadherin (CDH3) Human ELISA Kit

Description

The Human P-Cadherin (CDH3) ELISA quantitates Hu P-Cadherin in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu P-Cadherin. Principle of the method The Human P-Cadherin solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

P-cadherin, also known as Cadherin-3, is a Type 1 cadherin protein that belongs to the cadherin superfamily. Type 1 cadherins are single-pass transmembrane proteins that have 5 extracellular cadherin repeats and an intracellular domain that binds p120-catenin and beta-catenin. Cadherins are calcium-dependent cell-cell adhesion glycoproteins responsible for a range of processes including development, wound healing, cell-cell signaling, cell growth and differentiation. P-cadherin is expressed in human fetal structures, and in adult tissues such as the basal layer of the epidermis, breast, prostate, ovary, cervix, hair follicle, and corneal endothelium. P-cadherin expression has also been reported on embryonic stem cells, and stem cells of the normal mammary gland, and hair follicle. Overexpression of P-cadherin has been associated with poor prognosis in breast, prostate, ovary, colon, and stomach carcinomas. Mutations in CDH3 are associated with congential hypotrichosis with juvenile macular dystrophy.